The Valley Desk

ArticleCPT: pharmacometrics & systems pharmacologyPublished

Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
CPT: pharmacometrics & systems pharmacology
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Body Weight; Carboplatin; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Bispecific; Dose-Response Relationship, Drug; Mutation; Adult; Aged; Middle Aged
PubMed ID
42166539
PubMed Central ID
PMC13239558
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal